INBXInhibrx Biosciences, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet and insiders buying, but heavy debt (CCC) and big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Multiple insiders bought with their own money (net +$5.2M, 90 days to Oct 8, 2026).
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -44% · now 33% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can INBX take a bad year?
The deepest fall in INBX's price history on file is −44%; it is 33% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand, with no positive EBITDA to service it
- Altman Z-score
- 1.48
Altman Z-score · distress zone, below 1.8
- Cash runway
- 1.0 years
Cash runway · burning $33M a quarter at the current rate
- Annualised volatility
- 100%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $176M
- Cash and short-term investments
- $133M
- Net debt
- $43M
- EBITDA, trailing twelve months
- −$126M
- Operating profit, trailing twelve months
- −$128M
- Annualised volatilitytwo years of daily moves
- 100%
- Worst drawdown on file
- −44%
- Below its 52-week high
- 33%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry